ClinicalTrials.gg
CompletedNCT02579681StarTecUpdated Apr 27, 2017

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012

A Phase 3 interventional study of dimethyl fumarate in Multiple Sclerosis, Relapsing-Remitting, sponsored by Biogen. Completed at 18 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-27.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Apr 2014, registered Oct 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
221
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
6th of 22
221 · median 61
Started
2014
with 2 others
Phase 3
10 of 22
none open now
Registered
18th of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 6th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 3, and was the 18th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The primary objective(s) of the study are to assess the BG00012 (dimethyl fumarate) treatment effect on cognition over 2 year period in RRMS patients. The secondary objectives of this study are to further assess BG00012 treatment effect on cognition, predictors of cognitive impairment, clinical efficacy, and patient reported outcomes (PRO): depression, fatigue, quality of life, and work and social life activity.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Cognition
  • Tecfidera
  • RRMS
  • BG00012
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have a confirmed diagnosis of RRMS according to McDonald criteria (Polman, Reingold et al. 2005).
  • Must have a baseline EDSS between 0.0 and 5.0, inclusive.
  • Must have experienced at least 1 relapse within the 12 months prior to randomization, with a prior brain MRI demonstrating lesion(s) consistent with MS, or show evidence of gadolinium-enhancing lesion(s) of the brain on an MRI performed within the 6 weeks prior to randomization.

Key Exclusion Criteria:

Candidates will be excluded from study entry if any of the following exclusion criteria exist at the time of screening:

  • Primary progressive, secondary progressive, or progressive relapsing MS, as defined by Lublin and Reingold (Lublin and Reingold 1996)
  • Severe depression (MADRS score >34) (Montgomery and Asberg 1979)
  • History of (except basal cell carcinoma that has been completely excised prior to study enrollment)
  • An MS relapse that has occurred within the 30 days prior to inclusion AND/OR the participant has not stabilized from a previous relapse prior to inclusion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    BG00012

    BG00012 administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter.

    Drug: dimethyl fumarate

Interventions

  • dimethyl fumarate administered as per the arm description

    Also known as: Tecfidera, DMF, BG00012

06

What researchers measure

Primary outcomes

  1. Proportion of patients with worsening in cognitive improvement over 2 years.

    As measured by at least 2 standard deviation (SD) below Italian normative data of the Rao's Brief Repeatable Battery of Neuropsychological Tests (BRB) and a 100-item version of the Stroop Test. The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) is a sensitive measure of cognitive impairment in multiple sclerosis (MS) patients. The Stroop Test is a test used to measure a person's sustained attention for word reading and color naming with and without interference.

    Time frame: Up to 2 years

Secondary outcomes

  1. Change in cognitive impairment index score (CII) over two years

    An individual cognitive change index will be measured by calculating changes on the cognitive impairment index (CII) for each participant between year 0 and year 1, and year 0 and year 2. The CII is an individual cognitive change index aimed at providing a more precise assessment of the amount and direction of cognitive changes over time.

    Time frame: Up to 2 years

  2. Annualized relapse rate at year 1.

    Time frame: Up to one year

  3. Annualized relapse rate at year 2.

    Time frame: Up to 2 years

  4. Time to relapse over 2 years.

    Time frame: 2 years

  5. Proportion of patients with 6-month sustained progression of disability as measured by at least a 1.0 point increase from a baseline EDSS>1.0 or at least a 1.5 point increase from a baseline EDSS=0).

    The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. The EDSS quantifies disability in eight Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. Each functional system is scored on a scale of 0 (no disability) to 5 or 6 (more severe disability). EDSS steps 1.0 to 4.5 refer to people with MS who are fully ambulatory. EDSS steps 5.0 to 9.5 are defined by the impairment to ambulation.

    Time frame: Up to 2 years

  6. Assessment of baseline demographic, disease characteristics and related patient reported outcomes that predict CI at two years.

    Demographics may include age and gender, disease characteristics may include year of diagnosis and disability and PRO may include fatigue and depression at the time of initiation of BG00012.

    Time frame: Up to 2 years

  7. Change from baseline in a self rating version of the Montgomery and Asberg Depression Rating Scale (MADRS)

    The MADRS instrument has nine questions, with an overall score ranging from 0 to 27 points

    Time frame: 2 years

  8. Change from baseline in fatigue as measured by the Modified Fatigue Impact Scale (MFIS)

    The MFIS is a modified form of the Fatigue Impact Scale based on items derived from interviews with MS patients concerning how fatigue impacts their lives. This instrument provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning. The full-length MFIS consists of 21 items

    Time frame: 2 years

  9. Change from baseline in Quality of life (QOL) as measured by the EQ-5D Health Survey

    The EQ-5D is a widely-used survey instrument for measuring economic preferences for health states. It is a self-administered questionnaire consisting of 5 sets of 3 questions pertaining to specific health states (i.e., mobility, self-care, pain, usual activities, anxiety).

    Time frame: 2 years

  10. Change from baseline in the Environmental Status Scale (ESS)

    The Environmental Status Scale (ESS) is used to quickly evaluate a patient for handicap. It was derived from a measure of socio-economic status. It consists of seven parameters: (1) actual work status, (2) financial and economic status, (3) personal residence or home, (4) personal assistance required, (5) transportation, (6) community services, (7) social activity. Each parameter has a single score from minimum 0 to maximum 5. ESS score is the sum of the points for all 7 parameters: minimum score: 0; maximum score: 35. The higher the score the greater the handicap.

    Time frame: 2 years

07

Study locations

18 sites
  • Research site
    Bari, Italy
  • Research site
    Cagliari, Italy
  • Research site
    Catania, Italy
  • Research site
    Cefalu, Italy
  • Research site
    Chieti, Italy
  • Research site
    Ferrara, Italy
  • Research site
    Fidenza, Italy
  • Research site
    Firenze, Italy
  • Research site
    Gallarate, Italy
  • Research site
    Genova, Italy
  • Research site
    L'aquila, Italy
  • Research site
    Milano, Italy
  • Research site
    Napoli, Italy
  • Research site
    Orbassano, Italy
  • Research site
    Padova, Italy
  • Research site
    Palermo, Italy
  • Research site
    Pavia, Italy
  • Research site
    Roma, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Dec 2016, 31 months.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 31 months is below that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2015
First posted
Oct 20, 2015
StartActual
Apr 30, 2014
Primary completionActual
Dec 21, 2016
CompletionActual
Dec 21, 2016
Last update
Apr 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02579681
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 20, 2015
Start date
Apr 30, 2014
Primary completion
Dec 21, 2016
Completion
Dec 21, 2016
Last update
Apr 27, 2017

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion